Yatharth Hospital IPO : Yatharth Hospital Limited Ltd is coming up with its Initial Public Offering. The IPO will unshut for subscription on July 26, 2023, and tropical on July 28, 2023.

In this article, we will squint at the Yatharth Hospital IPO Review 2023 and unriddle its strengths and weaknesses. Keep reading to find out!

Yatharth Hospital IPO Review – About The Company

Yatharth Hospital and Trauma Superintendency Services Limited, founded in 2008, is a multi-care hospital network. In terms of the number of beds, two of its hospitals, namely, Noida Extension Hospital and Greater Noida are the 8th and 10th largest private hospitals in Delhi.

The visitor has three operational super speciality hospitals located in Delhi NCR and Uttar Pradesh. Additionally, the visitor has uninventive a 305-bedded multi-speciality hospital in Orchha, Madhya Pradesh near Jhansi which commenced operations in FY22. This makes it one of the largest hospitals in the JhansiOrchha-Gwalior region in terms of the number of beds.

The services provided by all its hospitals located in n Noida, Greater Noida and Noida Extension, in Uttar Pradesh have been rated “5 Star” by Infomerics Analytics and Research Private Limited in 2022.

As of FY23, the visitor has engaged 609 doctors and offers healthcare services wideness several specialities and super specialities. For increasingly focused patient care, the visitor has segmented the e pursuit super speciality as Centres of Excellence:

Services the company:

The services provided by the hospital include Multi-speciality tent cardiology, orthopaedics, neurology, renal sciences, oncology, trauma and hair-trigger care, laparoscopic and bariatric surgery, cosmetic and reconstructive surgery, rheumatology, dermatology, ophthalmology, etc.

Yatharth Hospital IPO – About The Industry

The healthcare industry is one of the largest industries in India, both in terms of employment and revenue. With the things like stabilisation of regular treatments, surgeries and OPD tween minimization of disruption due to the pandemic and expansion of ARPOB for the sector, the industry has unscientific to reach ₹ 5.6 trillion in value during FY23.

According to CRISIL forecasts, the Indian healthcare wordage industry will grow at a strong 11.3% CAGR between FY23 and FY27, reaching 8.6 trillion in Fiscal 2027. Long-term structural considerations, rising affordability, robust fundamentals, and the possibility of the Ayushman Bharat scheme are driving this.

Yatharth Hospital IPO Review – Financial Highlights

If we squint at the financials of Yatharth Hospital Ltd we find out that their resources have grown from ₹308.77 crores in March 2021 to ₹ 485.97 crores in March 2023.

Their revenues follow a similar trend, it has doubled from ₹229.19 crores in March 2021 to ₹523.10 crores in March 2023. Their profits have moreover grown from ₹19.59 crores in March 2021 to ₹65.77 crores in March 2023.

It is important to note that the company’s borrowing has moreover doubled from ₹186.11 crores In March 2021 to ₹263.78 crores on March 23.

The return ratios of the visitor show a steady increase over the last three years. The ROE and RoCE of the visitor for FY23 stood at 35.95% and 26.10% respectively.

Financial Metrics of the Company

(Source: RHP of the company)

Key Players in the Indian Pharmaceutical Market

The table image will requite you a list of the company’s listed peers withal with its revenue and other details:

Strengths of the Company

1) The company’s hospitals, namely, Noida Extension Hospital and Greater Noida are the 8th and 10th largest private hospitals in Delhi NCR, respectively, as of FY23.

Given the company’s market position and growing medical tourism in the Delhi NCR region, it has opportunities to build increasingly hospitals in existing and new markets as well as enhance its local polity presence.

2) The visitor is equipped with high-end machines and devices that squire its practitioners in providing timely, efficient and quality healthcare.

The wide infrastructure, technology and equipment have improved our operational efficiency and enhanced our patients’ experience.

3) The company’s success can partially be attributed to its qualified medical professionals and other staff, and its worthiness to vamp such quality professionals and staff.

The visitor offers a variety of engagement models, including a stock-still salary, minimum guarantee, and “service fee” models. These structures recoup the doctors for an increase in revenue, ensuring that they are motivated to retain their current patients and yank in new ones.

4) The visitor is led by a highly qualified and experienced management team who ensure that the visitor is led by the right mix of professionals from various fields.

Weaknesses of the Company

1) Failure to receive favourable pricing from its suppliers or the restriction to pass on s on any forfeit increases to its payers can adversely stupefy the profitability of the business. The visitor moreover deals with upper stock-still financing that can moreover impact its profitability.

2) The merchantry may get unauthentic if it is unable to secure or renew the approvals, licenses, registrations, and permits we need to run promptly, or plane at all.

3) Failure to vamp or retain doctors, nurses and other healthcare professionals can significantly impact the operations of the company.

4) The provision of healthcare services has upper financing such as manpower costs, upper medical equipment costs, and infrastructure maintenance and repair costs. The inability to pass on such financing to the patients may hurt our business,

5) The visitor derived 33.17% and 22.19% of its revenue from operations in FY21 and FY22 from COVID-19 which we may not protract to earn in future.

Yatharth Hospital IPO – Key IPO Information

Promoters: Ajay Kumar Tyagi And Kapil Kumar

Book Running Lead Manager: Intensive Fiscal Services Private Limited, Ambit Private Limited, IIFL Securities Limited.

Registrar to the Offer: Link Intime India Private Limited

The Objective of the Issue

Following are the Objectives of the issue by the company:

• Complete or partial repayment/prepayment of unrepealable borrowings availed by the company.
• Complete or partial repayment/prepayment of unrepealable borrowings availed by its Subsidiaries, namely, AKS Medical & Research Centre Private Limited (“AKS”) and Ramraja Multispeciality Hospital & Trauma Centre Private Limited (“Ramraja”).
• Funding wanted expenditure expenses of Noida Hospital and Greater Noida Hospital which are a part of the company
• Funding wanted expenditure expenses of AKS and Ramraja for the respective hospital operated by them.
• Funding variegated inorganic growth initiatives which include growth through acquisitions.
• General corporate purposes

Yatharth Hospital IPO Review – GMP

Currently we don’t have information on GMP, we shall update the vendible once we receive the information

In Closing

In this article, we looked at the details of Yatharth Hospital IPO Review 2023. Analysts remain divided on the IPO and its potential gains. This is a good opportunity for investors to squint into the visitor and unriddle its strengths and weaknesses. That’s it for this post.

Are you applying for the IPO? Let us know in the comments below.

Written by Aaron Vas

By utilizing the stock screener, stock heatmap, portfolio backtesting, and stock compare tool on the Trade Brains portal, investors proceeds wangle to comprehensive tools that enable them to identify the weightier stocks moreover get updated with stock market news, and make well-informed investment decisions

The post Yatharth Hospital IPO Review – GMP, Price, Date & Financials appeared first on Trade Brains.